Electromed ( (ELMD) ) has released its Q3 earnings. Here is a breakdown of the information Electromed presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Electromed, Inc. is a medical technology company based in New Prague, Minnesota, specializing in innovative airway clearance solutions, including the SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function.
In its fiscal 2025 third-quarter earnings report, Electromed announced its tenth consecutive quarter of year-over-year revenue and net income growth, highlighting strong operational execution and strategic market development initiatives.
The company reported a 13.1% increase in net revenue, reaching $15.7 million, with operating income rising by 16.2% to $2.1 million. Net income also saw a significant boost, climbing 26.7% to $1.9 million, or $0.21 per diluted share. The direct homecare business was a key driver, with revenue increasing by 14.8% due to more referrals and approvals, while non-homecare revenue remained stable. Electromed’s gross profit improved to 78% of net revenues, supported by higher net revenue per device.
Additionally, Electromed’s board approved a $5 million stock repurchase authorization, and the company maintained a strong cash position with $15.2 million in cash and no debt. Despite a slight decrease in cash due to share repurchases and tax payments, operating cash flow increased by $3 million year-over-year.
Looking ahead, Electromed remains focused on expanding its market presence and continuing its growth trajectory, leveraging its strategic initiatives and robust financial performance to create value for shareholders.